
b-rayZ is a Swiss med-tech company specializing in AI-powered breast imaging solutions to improve early breast cancer detection and patient outcomes. Founded as a spin-off from the University Hospital of Zurich, b-rayZ offers a modular, end-to-end AI platform that supports the entire breast diagnostic journey, providing real-time results with automatic BI-RADS ACR and image quality classifications. Their technology integrates seamlessly into existing IT infrastructures and device manufacturers, targeting radiologists, technicians, breast units, and patients. The company emphasizes clinical accuracy, workflow efficiency, and personalized diagnostic strategies, backed by extensive validation and certifications including CE marks and FDA registration. b-rayZ has achieved significant milestones including market entry in Europe and strategic partnerships, positioning itself as a leader in AI-driven breast cancer diagnostics with a strong focus on innovation, quality, and teamwork.

b-rayZ is a Swiss med-tech company specializing in AI-powered breast imaging solutions to improve early breast cancer detection and patient outcomes. Founded as a spin-off from the University Hospital of Zurich, b-rayZ offers a modular, end-to-end AI platform that supports the entire breast diagnostic journey, providing real-time results with automatic BI-RADS ACR and image quality classifications. Their technology integrates seamlessly into existing IT infrastructures and device manufacturers, targeting radiologists, technicians, breast units, and patients. The company emphasizes clinical accuracy, workflow efficiency, and personalized diagnostic strategies, backed by extensive validation and certifications including CE marks and FDA registration. b-rayZ has achieved significant milestones including market entry in Europe and strategic partnerships, positioning itself as a leader in AI-driven breast cancer diagnostics with a strong focus on innovation, quality, and teamwork.
Headquarters: Schlieren (Zurich), Switzerland
Founded: December 2019 (University Hospital of Zurich spin-off)
Product: Modular AI breast imaging platform (b-box, b-diagnose, b-box plus, DANAI)
Regulatory status: Multiple CE/MDR certifications and FDA Class I registration for a module
Recent financing: Series A announced June 30, 2025 (Affidea lead/strategic investor)
Breast imaging diagnostics and workflow optimization; early breast cancer detection.
2019
Medtech / Healthtech
Series A announced June 30, 2025; Affidea joined as strategic investor and preferred AI partner.
CHF 4,000,000
Oversubscribed Series A financing announced July 2022 with participation from foundations and private investors.
Innobooster grant awarded.
Early grant funding.
“Affidea (strategic investor) and participation from LifeCare Partners, Protagon AG, Convergence Partners, Eckenstein-Geigy Foundation and Swisspreneur syndicate”